Business Wire

Zambia sets global benchmark for community forest conservation

Share

Twelve communities in the Luangwa Valley are benefitting from direct cash payments of K50 million ($2.3 million) thanks to a partnership with forest conservation business BCP (BioCarbon Partners).

The ground-breaking Lower Zambezi REDD+ Project (LZRP) and Luangwa Community Forests Project (LCFP), facilitated by BCP in partnership with communities, the Zambian Forestry Department and Department of National Parks and Wildlife have resulted in direct monetisation of forest resources by local people.

The public-private-community projects set a new standard in forest conservation that puts the nation at the forefront of global efforts to combat climate change, while protecting forest resources and creating livelihood opportunities for local people.

His Royal Highness Chief Bunda Bunda said: “My community has worked hard towards this REDD+ verification success for Zambia. We thank the government for helping our Chiefdom to access REDD+ benefits and to BCP for the partnership, which has increased employment, livelihoods and development projects.”

LZRP is the world’s first REDD+ project to pass seven Verified Carbon Standard (VCS) audits, enabling income to be generated from credits that offset the carbon footprints of organisations producing greenhouse gases. LZRP was also the first REDD+ project in Africa to achieve triple-gold validation under the Climate, Community and Biodiversity Standard for exceptional social impact.

BCP CEO Dr Hassan Sachedina said: “We are privileged to support government and community efforts to conserve the Luangwa-Lower Zambezi ecosystem, one of the greatest remaining wildlife strongholds on earth.

“This has been a tough year due to the pandemic; tourism and conservation funding have declined, but through the extraordinary efforts of our partners such as Forestry Department, the LCFP has channelled K50 million into communities in 2020. We are grateful for USAID backing the LCFP’s development. This is just the beginning of a long-term, self-sustainable conservation model which benefits communities and wildlife”.

At 944,000 hectares, the triple-gold CCB validated LCFP is Africa’s largest project by hectares and improves the lives of 217,000 people in 12 chiefdoms, while LZRP covers 40,000 hectares and benefits 7,000 people in 1 chiefdom.

Ends

About BCP
BCP is a leading African conservation social enterprise with a mission to make wildlife habitat conservation valuable to people. BCP employs over 160 people across 13 chiefdoms in Zambia, partnering to help conserve 1 million hectares of habitat in critical ecosystems.
www.biocarbonpartners.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Gina Woolley
+260 763 299 406

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye